Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Connect with Takara Bio Europe at ELRIG Drug Discovery 2012

Published: Tuesday, September 04, 2012
Last Updated: Tuesday, September 04, 2012
Bookmark and Share
Connect with Takara Bio at booth M3 at the DD2012 in Manchester and win a Google Nexus 7 tablet.

Come along and discover more about kits for protein-protein interaction, cobalt purification media and fast expression systems.

Booth M3

Takara Bio Group

Since its beginnings as the biomedical business of Takara Shuzo Co., Ltd. (now Takara Holdings Inc.), Takara Bio has developed biotechnology-related businesses with a focus on genetic engineering technologies. At present, we have three business segments. In Japan, the Genetic engineering research business has pioneered the introduction and sale of a gene amplification system known as PCR (Polymerase Chain Reaction). This business provides research reagents, scientific instruments, and contract research services that are essential for leading-edge biotechnology research. Today, the sales network of this business boasts a global reach, encompassing North America, Europe, and emerging Asian countries.Place description here

Clontech Laboratories, Inc.

Clontech Laboratories provides kits, reagents, and services that help researchers explore questions about gene discovery, regulation, and function. As the newest member of the Takara Bio Group, Clontech joins a company that holds a leadership position in the global market and is committed to improving the human condition through biotechnology. Clontech's mission is to develop high-quality innovative tools and services to accelerate discovery.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Drugs that May Combat Deadly Antibiotic-Resistant Bacteria Uncovered
Study identifies 79 compounds that inhibit carbapenem-resistant Enterobacteriaceae (CRE).
Making Precision Medicine a Reality
Researchers are one step closer to understanding the genetic and biological basis of diseases like cancer, diabetes, Alzheimer’s and rheumatoid arthritis – and identifying new drug targets and therapies.
Potential “Good Fat” Biomarker
New method to measure the activity of energy consuming brown fat cells could ease the testing weight loss drugs.
MicroRNA Pathway Could Lead to New Avenues for Leukemia Treatment
Cancer researchers at the University of Cincinnati have found a particular signaling route in microRNA (miR-22) that could lead to targets for acute myeloid leukemia, the most common type of fast-growing cancer of the blood and bone marrow.
Soy Shows Promise as Natural Anti-Microbial Agent
Soy isoflavones and peptides may inhibit the growth of microbial pathogens that cause food-borne illnesses, according to a new study from University of Guelph researchers.
Doubling Down on Dengue
HMS researchers have discovered two ways a compound blocks dengue virus.
Soy Shows Promise as Natural Anti-Microbial Agent
Researchers from University of Guelph show that soy isoflavones and peptides could be used to reduce microbial contamination of food.
AstraZeneca to Sequence 2 Million Genomes in Search for New Drugs
Company launches integrated genomics approach which aims to transform drug discovery and development.
Unique Model for Studying ALS
Unique mouse model will allow researchers to better study the genetic origins and potential treatments of ALS.
Targeting an ‘Undruggable’ Cancer Gene
RAS genes are mutated in more than 30 percent of human cancers and represent one of the most sought-after cancer targets for drug developers.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!